Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.
Phase 2
- Conditions
- unresectable colorectal cancer
- Registration Number
- JPRN-UMIN000011364
- Lead Sponsor
- Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
PS 3
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Adverse event, Overall survival,Disease-free survival